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EDITORIAL
COX2 selective NSAIDs and renal function:
Gain without pain?
Non-steroidal anti-inflammatory drugs (NSAIDs) are nemic-hypoaldosteronism and hyperkalemic (type IV)
among the most widely prescribed class of pharmaceuti- renal tubular acidosis. Recent studies suggest that COX2
cal agents world-wide, having broad clinical utility in may play a role in these events. As opposed to other
treating pain, fever, and inflammation [1]. Despite a rela- tissues, relatively abundant COX2 expression is detected
tively low incidence of side-effects, because of their exten- in the kidney constitutively [5, 6]. The intrarenal sites
sive use and ready accessibility, they remain a significant of COX2 expression are intriguing. COX2 mRNA is
cause of gastrointestinal ulceration and renal disease. localized not only to the macula densa (and a sub-set of
Both the therapeutic and deleterious side effects of surrounding cells in the cortical thick ascending limb)
NSAIDs are thought to be primarily mediated by their but also to renal medullary interstitial cells. The impor-
capacity to inhibit prostaglandin forming cyclooxygen- tance of macula densa COX2-derived prostaglandins to
ases [2]. The recent discovery that prostaglandin forma- the regulation of renin release and glomerular hemody-
tion is mediated by not one, but two different cyclooxy- namics is beginning to be characterized, and data sug-
genase isoforms (designated COX1 and COX2), has gests that macula densa COX2 expression is intertwined
prompted much excitement focused upon the possibility with dietary Na1 intake and renin synthesis [5, 7]. If so,
that one COX isoform might be the therapeutic target COX2 selective inhibitors might not represent a signifi-
of NSAIDs, while the other is responsible for their unde- cant improvement over non-selective NSAIDs with re-
sired side effects [2]. Indeed, several studies demonstrate spect to reduced GFR and hyperkalemia. Similar consid-
that COX2 expression, which is normally low, is mark- erations may pertain to maintenance of renal medullary
edly increased by inflammatory cytokines and suppressed blood flow by prostaglandins produced by COX2 in med-
by anti-inflammatory glucocorticoids, supporting its role ullary interstitial cells [6]. Interestingly, medullary inter-
as a therapeutic target. In contrast, appreciable levels of stitial cells are also an early target of injury in analgesic
COX1 are expressed in normal tissues, and are unchanged nephropathy, and inhibition of prostaglandin formation
by cytokines, growth factors or glucocorticoids, consistent by these cells may have relevance to the development
with a role for COX1 in maintaining normal tissue integ- of papillary necrosis observed with chronic NSAID use
rity. The idea that COX1 inhibition is bad while COX2 [8]. The preceding considerations pertain to situations
inhibition is therapeutic has been bolstered by more re- where NSAIDs are administered to treat pain or sys-
cent findings that COX2 selective NSAIDs relieve pain temic inflammatory conditions that do not involve the
and inflammation while sparing the gastrointestinal tract kidney. They may not address the particular role that
[2, 3]. The possibility that COX2 selective inhibitors will COX2 plays when the kidney is the site of inflammation.
similarly spare renal function is less clear-cut.
In this issue of Kidney International, Schneider et al
An important relationship between prostaglandin
report initial studies examining the renal effects of COX2
forming cyclooxygenases and the maintenance of normal
selective inhibitors in glomerulonephritis (GN) [9]. The
renal function has long been appreciated. A role for
authors compared the effects of two relatively selectiveprostaglandins in maintaining glomerular filtration rate
COX2 inhibitors (meloxicam and SC-58125) with those(GFR) and renal medullary blood flow during volume
of a non-selective COX2 inhibitor, indomethacin. Alldepletion is particularly well established [4]. The use
three NSAIDs augmented the glomerular production ofof NSAIDs in volume depleted patients or those with
two chemokines: monocyte chemoattractant protein-1underlying chronic renal insufficiency or cirrhosis is asso-
(MCP-1) and RANTES, suggesting endogenous prosta-ciated with risk of acute renal failure and/or acute tubular
glandins normally suppress renal chemokine formation.necrosis [4]. NSAID use is also associated with hyporeni-
Induction of MCP-1 and RANTES was particularly pro-
nounced in those animals treated with indomethacin,
versus modest induction seen in animals treated withKey words: cyclooxygenase, inflammation, toxicity, hemodynamics, an-
algesic nephropathy. COX2 inhibitors. Importantly, increased monocyte/mac-
rophage infiltration was observed only in those animals 1999 by the International Society of Nephrology
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treated with the non-selective NSAID indomethacin, hoped that future studies will demonstrate they spare
not only the gastrointestinal tract, but the kidney as well.and was not observed in those animals treated with
COX2 selective inhibitors. The more impressive pro-
Mathew D. Breyerinflammatory effects of indomethacin support a role for
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COX1 products in suppressing inflammation, actions
that would not be suppressed by COX2 inhibitors. Given ACKNOWLEDGMENTS
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